IDH enzymes normally convert isocitrate to α-ketoglutarate (αKG). However, cancer-associated IDH mutations result in an enzyme that converts αKG to 2-hydroxyglutarate (2HG). 2HG can competitively ...
CAMBRIDGE, MASS. – April 4, 2013 – Foundation Medicine, Inc., and Agios Pharmaceuticals, Inc., today announced a multi-year diagnostic partnership for Agios' lead programs in cancer metabolism. These ...
The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...
Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic mutations—IDH2 and SRSF2—work cooperatively to mis-splice RNA messages and ...
The genes encoding IDH1/2 and BRAF are frequently altered in low-grade glioma; the presence or absence of these alterations should be determined in all patients. Maximal safe tumor resection remains ...
SEPTEMBER 20, 2023, NEW YORK – In exploring an aspect of how killer T cells generate the raw materials required for their proliferation, a Ludwig Cancer Research study has uncovered an unexpected link ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results